Axa S.A. Acquires 41,722 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

AXA S.A. grew its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 20.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 249,702 shares of the company's stock after buying an additional 41,722 shares during the quarter. AXA S.A. owned 0.29% of IDEAYA Biosciences worth $6,417,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Barclays PLC grew its holdings in IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after buying an additional 118,438 shares in the last quarter. Geode Capital Management LLC lifted its stake in IDEAYA Biosciences by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after purchasing an additional 43,226 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after acquiring an additional 15,089 shares in the last quarter. JPMorgan Chase & Co. increased its stake in IDEAYA Biosciences by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock worth $2,527,000 after purchasing an additional 12,029 shares in the last quarter. Finally, WCM Investment Management LLC purchased a new position in shares of IDEAYA Biosciences in the fourth quarter worth approximately $6,030,000. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Price Performance

Shares of IDYA traded up $0.90 during midday trading on Monday, hitting $18.32. The stock had a trading volume of 215,658 shares, compared to its average volume of 987,640. The company has a 50 day simple moving average of $17.74 and a two-hundred day simple moving average of $22.59. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -5.56 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the company posted ($0.53) earnings per share. Analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Stephens reiterated an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.